These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11776336)

  • 1. Modification of von Willebrand disease after liver transplantation.
    Schulman S; Ericzon BG; Eleborg L
    Thromb Haemost; 2001 Dec; 86(6):1588-9. PubMed ID: 11776336
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on the management of von Willebrand disease.
    Federici AB
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):29-30. PubMed ID: 18322438
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant von Willebrand factor.
    Schwarz HP; Turecek PL; Pichler L; Mitterer A; Mundt W; Dorner F; Roussi J; Drouet L
    Thromb Haemost; 1997 Jul; 78(1):571-6. PubMed ID: 9198218
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of D-arginine vasopressin in von Willebrand's disease.
    Bala L; Boggio L; Green D
    Curr Hematol Rep; 2005 Jan; 4(1):1-2. PubMed ID: 15610653
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular basis of von Willebrand disease and its clinical implications.
    Haematologica; 2004 Sep; 89(9):1036. PubMed ID: 15377463
    [No Abstract]   [Full Text] [Related]  

  • 6. [Willebrand disease].
    Lequièvre V
    Rev Infirm; 2006; (122):22-4. PubMed ID: 16881452
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease.
    Trossaërt M; Flaujac C; Jeanpierre E; Drillaud N; Sigaud M; Fouassier M; Ternisien C; de Raucourt E
    Haemophilia; 2020 Mar; 26(2):e44-e48. PubMed ID: 31865618
    [No Abstract]   [Full Text] [Related]  

  • 8. Prophylaxis in von Willebrand disease.
    Franchini M; Targher G; Lippi G
    Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Willebrand disease update: diagnostic and treatment dilemmas.
    Bolton-Maggs PH; Lillicrap D; Goudemand J; Berntorp E
    Haemophilia; 2008 Jul; 14 Suppl 3():56-61. PubMed ID: 18510523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An inherited hemostatic disorder as the cause of menorrhagia].
    Leebeek FW; Lotgering FK
    Ned Tijdschr Geneeskd; 2002 Mar; 146(12):545-8. PubMed ID: 11938574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic impact of orthotopic liver transplantation on disorders of hemostasis.
    Fischbach P; Scharrer I
    Semin Thromb Hemost; 1993; 19(3):250-7. PubMed ID: 8395707
    [No Abstract]   [Full Text] [Related]  

  • 14. Common bleeding disorders: a potential catastrophe for the trauma victim. Therapeutic recommendations for the treatment of von Willebrand's disease.
    Slam K; Zyromski N; Nowicki P; Serrano P; Purtill MA
    J Trauma; 2008 May; 64(5):1373-5. PubMed ID: 18469664
    [No Abstract]   [Full Text] [Related]  

  • 15. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 1 von Willebrand disease: application of emerging data to clinical practice.
    Collins PW; Cumming AM; Goodeve AC; Lillicrap D
    Haemophilia; 2008 Jul; 14(4):685-96. PubMed ID: 18510569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acquired von Willebrand syndrome].
    de Lange DW; Fijnheer R; Wittebol S
    Ned Tijdschr Geneeskd; 2003 Sep; 147(37):1808-11. PubMed ID: 14526622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD; Kunz D; Wirtz DC
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inborn and acquired von Willebrand disease].
    Schneppenheim R; Barthels M; Budde U
    Hamostaseologie; 2005 Nov; 25(4):367-75. PubMed ID: 16395486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.